Table 1. Demographic characteristics.
|
Number (%) or median (range) |
|
||
|---|---|---|---|
| Development group | Validation group | P-value | |
| No. of patients |
1620 |
538 |
|
| Age (years) |
49.3 (19.7–83.0) |
48.7 (26.9–78.0) |
|
|
Stage | |||
| IB1 | 1243 (76.7) | 416 (77.3) | ns |
| IB2 | 190 (11.7) | 50 (9.3) | |
| IIA |
187 (11.5) |
72 (13.4) |
|
|
Histology | |||
| SCC | 1234 (76.2) | 403 (74.9) | ns |
| Adeno | 271 (16.7) | 90 (16.7) | |
| Adenosquamous | 78 (4.8) | 37 (6.9) | |
| Other |
37 (2.3) |
8 (1.5) |
|
| Tumour size (cm) |
2.8 (1.0–7.0) |
2.7 (1.0–7.0) |
ns |
|
DSI | |||
| Inner 1/3 | 593 (36.6) | 183 (34.0) | ns |
| Middle 1/3 | 472 (29.1) | 171 (31.8) | |
| Outer 1/3 |
555 (34.3) |
184 (34.2) |
|
|
LVSI | |||
| Positive | 505 (31.2) | 166 (30.9) | ns |
| Negative |
1115 (68.8) |
372 (69.1) |
|
|
Intermediate-risk grouping | |||
| Classic criteria (+) | 1034 (63.8) | 344 (63.9) | ns |
| GOG criteria (+) |
585 (36.1) |
190 (35.3) |
|
|
Adjuvant treatment | |||
| Yes | 425 (26.2) | 143 (26.6) | ns |
| RT or CRT | 331 (20.4) | 109 (20.3) | |
| Chemotherapy | 94 (5.8) | 34 (6.3) | |
| No |
1195 (73.8) |
395 (73.4) |
|
| Follow-up duration (months) |
64.0 (0.2–234.0) |
64.6 (0.2–231.0) |
ns |
| Recurrence | 131/1620 (8.1) | 44/538 (8.2) | ns |
| Classic criteria (+) | 103/1034 (10.0) | 30/344 (8.7) | |
| GOG criteria (+) |
71/585 (12.1) |
18/190 (9.5) |
|
|
Status | |||
| Died | 78 (4.8) | 27 (5.0) | ns |
| Alive | 1533 (94.6) | 510 (94.8) | |
Abbreviations: CRT=concurrent chemoradiation; DSI=deep stromal invasion; GOG=Gynecologic Oncology Group; LVSI=lymphovascular space involvement; ns=not significant; RT=radiation therapy; SCC=squamous cell carcinoma.